Association of NCCN-Recommended Posttreatment Surveillance With Outcomes in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma | Cancer Screening, Prevention, Control | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
National Comprehensive Cancer Network. NCCN guidelines. Head and neck cancer. http://www.nccn.org/professionals/physician_gls/ pdf/head-and-neck.pdf. Accessed March 23, 2019.
2.
Schwartz  LH, Ozsahin  M, Zhang  GN,  et al.  Synchronous and metachronous head and neck carcinomas.  Cancer. 1994;74(7):1933-1938. doi:10.1002/1097-0142(19941001)74:7<1933::AID-CNCR2820740718>3.0.CO;2-XPubMedGoogle ScholarCrossref
3.
Cooney  TR, Poulsen  MG.  Is routine follow-up useful after combined-modality therapy for advanced head and neck cancer?  Arch Otolaryngol Head Neck Surg. 1999;125(4):379-382. doi:10.1001/archotol.125.4.379PubMedGoogle ScholarCrossref
4.
Schwartz  DL, Barker  J  Jr, Chansky  K,  et al.  Postradiotherapy surveillance practice for head and neck squamous cell carcinoma: too much for too little?  Head Neck. 2003;25(12):990-999. doi:10.1002/hed.10314PubMedGoogle ScholarCrossref
5.
Agrawal  A, deSilva  BW, Buckley  BM, Schuller  DE.  Role of the physician versus the patient in the detection of recurrent disease following treatment for head and neck cancer.  Laryngoscope. 2004;114(2):232-235. doi:10.1097/00005537-200402000-00011PubMedGoogle ScholarCrossref
6.
Agrawal  A, Hammond  TH, Young  GS, Avon  AL, Ozer  E, Schuller  DE.  Factors affecting long-term survival in patients with recurrent head and neck cancer may help define the role of post-treatment surveillance.  Laryngoscope. 2009;119(11):2135-2140. doi:10.1002/lary.20527PubMedGoogle ScholarCrossref
7.
Flynn  CJ, Khaouam  N, Gardner  S,  et al.  The value of periodic follow-up in the detection of recurrences after radical treatment in locally advanced head and neck cancer.  Clin Oncol (R Coll Radiol). 2010;22(10):868-873. doi:10.1016/j.clon.2010.05.016PubMedGoogle ScholarCrossref
8.
Kothari  P, Trinidade  A, Hewitt  RJD, Singh  A, O’Flynn  P.  The follow-up of patients with head and neck cancer: an analysis of 1,039 patients.  Eur Arch Otorhinolaryngol. 2011;268(8):1191-1200. doi:10.1007/s00405-010-1461-2PubMedGoogle ScholarCrossref
9.
Malik  A, Sahu  A, Singh  SP,  et al.  In vivo Raman spectroscopy-assisted early identification of potential second primary/recurrences in oral cancers: An exploratory study.  Head Neck. 2017;39(11):2216-2223. doi:10.1002/hed.24884PubMedGoogle ScholarCrossref
10.
Chaturvedi  AK, Engels  EA, Pfeiffer  RM,  et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.  J Clin Oncol. 2011;29(32):4294-4301. doi:10.1200/JCO.2011.36.4596PubMedGoogle ScholarCrossref
11.
Ang  KK, Harris  J, Wheeler  R,  et al.  Human papillomavirus and survival of patients with oropharyngeal cancer.  N Engl J Med. 2010;363(1):24-35. doi:10.1056/NEJMoa0912217PubMedGoogle ScholarCrossref
12.
Frakes  JM, Naghavi  AO, Demetriou  SK,  et al.  Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.  Cancer. 2016;122(4):634-641. doi:10.1002/cncr.29782PubMedGoogle ScholarCrossref
13.
Corpman  DW, Masroor  F, Carpenter  DM, Nayak  S, Gurushanthaiah  D, Wang  KH.  Posttreatment surveillance PET/CT for HPV-associated oropharyngeal cancer.  Head Neck. 2019;41(2):456-462. doi:10.1002/hed.25425PubMedGoogle Scholar
14.
Newman  TB, Brown  AN.  Use of commercial record linkage software and vital statistics to identify patient deaths.  J Am Med Inform Assoc. 1997;4(3):233-237. doi:10.1136/jamia.1997.0040233PubMedGoogle ScholarCrossref
15.
Pagh  A, Vedtofte  T, Lynggaard  CD,  et al.  The value of routine follow-up after treatment for head and neck cancer: a national survey from DAHANCA.  Acta Oncol. 2013;52(2):277-284. doi:10.3109/0284186X.2012.741324PubMedGoogle ScholarCrossref
16.
Ilmarinen  T, Keski-Säntti  H, Markkanen-Leppänen  M,  et al.  De-escalation of post-treatment surveillance in oropharyngeal cancer.  Head Neck. 2019;41(5):1457-1462. doi:10.1002/hed.25593PubMedGoogle ScholarCrossref
17.
Denaro  N, Merlano  MC, Russi  EG.  Follow-up in head and neck cancer: do more does it mean do better? a systematic review and our proposal based on our experience.  Clin Exp Otorhinolaryngol. 2016;9(4):287-297. doi:10.21053/ceo.2015.00976PubMedGoogle ScholarCrossref
18.
Bledsoe  TJ, Noble  AR, Hunter  GK,  et al.  Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomes.  Radiat Oncol. 2013;8(1):174. doi:10.1186/1748-717X-8-174PubMedGoogle ScholarCrossref
Original Investigation
August 8, 2019

Association of NCCN-Recommended Posttreatment Surveillance With Outcomes in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Author Affiliations
  • 1Department of Head and Neck Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California
  • 2San Francisco School of Medicine, University of California, San Francisco, San Francisco
  • 3Division of Research, Kaiser Permanente Northern California, Oakland, California
  • 4Graduate Medical Education, Kaiser Permanente Medical Center, Oakland, California
  • 5Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles
JAMA Otolaryngol Head Neck Surg. 2019;145(10):903-908. doi:10.1001/jamaoto.2019.1934
Key Points

Question  Is National Comprehensive Cancer Network (NCCN)–recommended posttreatment clinical surveillance in patients with human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (SCC) associated with improvements in recurrence detection and survival outcomes?

Findings  In this cohort study of 233 patients with HPV–associated oropharyngeal SCC, only 1 asymptomatic recurrence was detected of 3358 posttreatment clinical surveillance visits, and adherence to the recommended schedule did not seem to improve survival.

Meaning  The findings of this study suggest that reduction of the NCCN-recommended posttreatment clinical surveillance schedule for HPV–associated oropharyngeal SCC is warranted.

Abstract

Importance  National Comprehensive Cancer Network (NCCN) guidelines recommend routine clinical follow-up as posttreatment surveillance for patients with head and neck cancer (HNC). Human papillomavirus–associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC) is a unique subset of HNC, associated with fewer recurrences and improved survival. The utility of this guideline in this patient population is unknown.

Objective  To determine adherence to the NCCN clinical follow-up guideline, frequency of recurrence detection method, classified as symptom-directed, physician-detected, or imaging-detected, and survival benefit associated with adherence to the NCCN guideline.

Design, Setting, and Participants  Retrospective cohort study of patients with HPV-associated OPSCC diagnosed between January 1, 2011, and April 30, 2014, at a large integrated health care system. Multivariable analyses were conducted using the Cox proportional hazards regression model, with patient adherence to NCCN visit guidelines constructed as a time-dependent variable. All data analyses were complete on September 1, 2018.

Exposures  Posttreatment clinical and imaging surveillance.

Main Outcomes and Measures  Recurrence and overall survival. Secondary outcome was salvage therapy.

Results  Of the 233 study patients with HPV-associated OPSCC, the mean (SD) age at diagnosis was 60.5 (8.7) years; 201 (86.3%) were male, 189 (81.1%) were white, and 109 (46.8%) had a positive smoking history. Median follow-up time through recurrence or all-cause mortality was 4.5 years (interquartile range, 3.8-5.6). Patients demonstrated 83.0% (180 of 217) adherence to NCCN surveillance guidelines in year 1, 52.7% (106 of 201) in year 2, 73.4% (141 of 192) in year 3, 62.3% (96 of 154) in year 4, and 52.9% (45 of 85) in year 5. A total of 3358 clinical surveillance examinations were performed with 22 patients having recurrences. There were 10 symptom-directed, 1 physician-detected, and 11 imaging-detected recurrences. Of the symptom-directed recurrences, salvage therapy was attempted in 5; at the study end date, 1 was alive. Salvage neck dissection was attempted in the physician-detected recurrence; this patient subsequently died. All locoregional recurrences occurred within the first 2 years, and all salvageable recurrences within the first year. Adherence to NCCN guidelines was not protective against all-cause mortality in the multivariable Cox proportional hazards regression model (hazard ratio, 0.76; 95% CI, 0.28-2.05).

Conclusions and Relevance  Among patients with HPV-associated OPSCC, clinical surveillance is of limited utility. Nearly all clinically detected recurrences were elicited by patient symptoms that prompted earlier presentation to the clinician. Adherence to the current schedule does not appear to confer survival advantage, and locoregional recurrences are almost never detected beyond 2 years. These findings support reduction of posttreatment clinical surveillance in this population.

×